Allergen Immunotherapy and Possible Clinical Remission: Toward a Disease-Modifying Paradigm in Allergic Disorders

Allergen immunotherapy (AIT) represents the only disease-modifying treatment currently available for IgE-mediated allergic diseases. Traditionally employed to alleviate symptoms and reduce pharmacological dependence, AIT is now being reconsidered within a broader and more ambitious therapeutic framework: the induction of long-term clinical remission. In the field of allergic diseases, the concept of disease control has recently been integrated with that of clinical remission. This review discusses the evolving concept of remission in allergic disorders, particularly allergic rhinitis and allergic asthma, in patients treated with AIT. Starting from the definition of clinical remission, this review aims to analyze the evidence supporting this concept and explore potential tools for clinical application in allergic patients treated with AIT, the only causal therapy.